Douglas Kerr of the biotech firm Biogen Idec discusses the disappointing results of the phase 3 'EMPOWER' trial of the experimental ALS drug dexpramipexole

Posted on Tuesday, January 15, 2013 - 11:52, By: Amy Madsen

Biogen Idec has announced that the experimental ALS drug has not shown efficacy in a large-scale trial; its development will be discontinued

Posted on Thursday, January 3, 2013 - 02:41, By: Margaret Wahl
Biotechnology company Biogen Idec today announced disappointing results from its phase 3 trial of dexpramipexole, an experimental drug the company has been developing to treat amyotrophic lateral sclerosis (ALS).

Biogen Idec is recruiting participants for its 'EMPOWER' trial, which will study the effects of the experimental treatment dexpramipexole in ALS

Posted on Thursday, March 31, 2011 - 05:30, By: Amy Madsen
Update 8/31/11: Enrollment screening for this study has closed to new prospective participants.